Smith Richard JH, Azaiez Hela, Odell Amanda M
Sterba Hearing Research Professor of Otolaryngology;, Director, Molecular Otolaryngology and Renal Research Laboratories, Department of Otolaryngology – Head & Neck Surgery, Carver College of Medicine, University of Iowa, Iowa City, Iowa
Molecular Otolaryngology and Renal Research Laboratories, Department of Otolaryngology – Head & Neck Surgery, Carver College of Medicine, University of Iowa, Iowa City, Iowa
-related sensorineural hearing loss (-SNHL), characterized by inner ear malformations also associated with vestibular dysfunction, comprises two phenotypes: (1) nonsyndromic -SNHL (also referred to as DFNB4 or nonsyndromic enlargement of the vestibular aqueduct [NSEVA]) and (2) Pendred syndrome (PDS) that includes thyroid involvement (typically identified more frequently in countries without universal salt iodization programs). The time of onset and type of presentation of the SNHL vary (such that some newborns pass their newborn hearing screening); however, by age three years most children have bilateral and severe-to-profound hearing loss. Manifestations of vestibular dysfunction (such as head-tilting, vomiting, and/or delayed ambulation or clumsiness in a child who previously walked well) can precede or accompany the fluctuations in hearing typical of this disorder. Thyroid enlargement (goiter) occurs gradually and is typically evident in the second decade, especially if iodine is not routinely included in the diet.
DIAGNOSIS/TESTING: The diagnosis of -SNHL is established in a proband with suggestive findings and biallelic pathogenic variants in identified by molecular genetic testing
Supportive treatment includes multidisciplinary care by specialists in hearing habilitation, as early auditory intervention is critical to the development of speech and language. Habilitation options tailored to the degree and frequency of hearing loss can include hearing aids when hearing loss is mild to severe and consideration of cochlear implantation (CI) when hearing aids have had limited benefit. When considering CI, it is essential that the treating otolaryngologist be aware of the possible perioperative complications (most commonly perilymph gusher/oozing) and postoperative complications (most commonly transient vertigo) in individuals with -SNHL. Educational and early intervention programs designed for individuals with hearing loss are recommended. Medical treatment of thyroid enlargement and/or abnormal thyroid function requires consultation with an endocrinologist. Audiometric testing every three to six months until age three years and annually thereafter; baseline ultrasound to assess thyroid size at age ten years, followed by repeat ultrasound every five to ten years based on findings on palpation of thyroid size. Follow standard recommendations for individuals with hearing loss. Despite anecdotal reports that head injuries resulting in increased intracranial pressure in individuals with enlarged vestibular aqueduct can occasionally trigger a decline in hearing, evidence is insufficient to support that avoidance of these activities decreases the overall risk of progression of hearing loss. While health care providers should alert families to this possible association, it is recommended that families be encouraged to make their own decisions on participation in contact sports. It is appropriate to determine the genetic status of at-risk sibs of a proband with -SNHL (i.e., a proband with known biallelic pathogenic variants) shortly after birth so that appropriate and early support and management can be provided to the child and family.
-SNHL is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an pathogenic variant, each sib of the proband has at conception a 25% chance of having -SNHL, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the pathogenic variants. Once biallelic pathogenic variants have been identified in the proband, heterozygote testing for relatives of an individual with -SNHL and prenatal/preimplantation genetic testing are possible.
与内耳畸形相关的感音神经性听力损失(-SNHL),也与前庭功能障碍有关,包括两种表型:(1)非综合征性-SNHL(也称为DFNB4或前庭导水管非综合征性扩大[NSEVA])和(2) Pendred综合征(PDS),包括甲状腺受累(在没有普遍食盐碘化计划的国家中通常更常见)。SNHL的发病时间和表现类型各不相同(例如,一些新生儿通过了新生儿听力筛查);然而,到三岁时,大多数儿童会出现双侧重度至极重度听力损失。前庭功能障碍的表现(如头部倾斜、呕吐和/或先前行走良好的儿童出现行走延迟或笨拙)可能先于或伴随这种疾病典型的听力波动出现。甲状腺肿大(甲状腺肿)逐渐出现,通常在第二个十年明显,特别是如果饮食中不常规添加碘。
诊断/检测:通过分子基因检测在具有提示性发现和双等位基因致病变异的先证者中确立-SNHL的诊断。
支持性治疗包括听力康复专家的多学科护理,因为早期听觉干预对言语和语言发展至关重要。根据听力损失的程度和频率量身定制的康复选择,听力损失为轻度至重度时可包括助听器,当助听器效果有限时可考虑人工耳蜗植入(CI)。考虑人工耳蜗植入时,治疗耳鼻喉科医生必须了解-SNHL患者可能的围手术期并发症(最常见的是外淋巴瘘/渗出)和术后并发症(最常见的是短暂性眩晕)。建议为听力损失患者设计教育和早期干预计划。甲状腺肿大和/或甲状腺功能异常的药物治疗需要咨询内分泌科医生。三岁前每三到六个月进行一次听力测试,此后每年进行一次;十岁时进行基线超声检查以评估甲状腺大小,然后根据甲状腺大小触诊结果每五到十年重复进行超声检查。遵循针对听力损失患者的标准建议。尽管有轶事报道称,导致前庭导水管扩大的个体颅内压升高的头部损伤偶尔会引发听力下降,但证据不足以支持避免这些活动会降低听力损失进展的总体风险。虽然医疗保健提供者应提醒家庭注意这种可能的关联,但建议鼓励家庭自行决定是否参加接触性运动。在出生后不久确定-SNHL先证者(即具有已知双等位基因致病变异的先证者)的高危同胞的基因状态是合适的,以便为儿童和家庭提供适当的早期支持和管理。
-SNHL以常染色体隐性方式遗传。如果已知父母双方均为致病变异的杂合子,先证者的每个同胞在受孕时有25%的机会患有-SNHL,50%的机会为杂合子,25%的机会既不继承任何一个致病变异。一旦在先证者中确定了双等位基因致病变异,就可以对-SNHL个体的亲属进行杂合子检测以及产前/植入前基因检测。